BioAge Labs, Inc. (BIOA): Shareholders' Equity
$272.05M
As of 2025-12-31
$374.91M
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $272.05M | -15.8% | 2026-03-24, Balance as of period end |
| 2024-12-31 | $323.13M | n/m | 2026-03-24, Balance as of period end |
| 2023-12-31 | -$173.40M | n/a | 2025-03-20, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $272.05M | -15.8% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | -$4.06M | n/m |
| Precigen, Inc. (PGEN) | 2025-12-31 | $20.91M | -45.7% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $280.47M | -42.4% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $4.53B | -3.4% |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $956.82M | -6.4% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $242.14M | -22.5% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $43.03M | +8.7% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $103.08M | -33.7% |
Compare BIOA, ISCO, PGEN, PRTA side by side · Screen every company in Pharmaceutical Preparations ↗